Published: 6 March 2025
Publications
MARC’s remarks: December 2024 meeting
Published: 6 March 2025
Prescriber Update 46(1): 8
March 2025
The Medicines Adverse Reaction Committee (MARC) convened for their 200th meeting on 5 December 2024.
The Committee discussed the risk of cutaneous vasculitis with direct-acting oral anticoagulants (DOACs). The Committee noted that the cause of this condition can be difficult to identify and may be due to medicines or an autoimmune reaction. On review of the data presented, the Committee concluded that there is a risk of cutaneous vasculitis with DOACs and recommended data sheet updates for approved DOACs.
The Committee reviewed the Risk Management Plan (RMP) for Jynneos (vaccina vaccine). They noted that myo-/pericarditis is an important potential risk in the RMP, but there is no information on myo-/pericarditis in the data sheet. The Committee considered that it would be helpful for healthcare professionals to know about this potential risk and recommended that the data sheet be updated with this information. They also recommended that Medsafe update the currently published monitoring communication on reports of pericarditis following mpox vaccination.
At the meeting, the Committee further discussed clozapine blood monitoring requirements following on from the report presented at the September 2024 MARC meeting. The Committee agreed that changes to the blood monitoring requirements for clozapine are needed. They recommended that Medsafe should further review possible options for changes and seek additional expert advice.
See the Medsafe website for the MARC meeting minutes and the reports presented to the MARC.
